文献速递淋巴瘤

慢性淋巴细胞白血病与单克隆B细胞增多症患者对重组带状疱疹疫苗的免疫应答

Humoral and cellular immune responses to recombinant herpes zoster vaccine in patients with chronic lymphocytic leukemia and monoclonal B cell lymphocytosis.
PubMed 文献 · Am J Hematol · 2021-11-05

研究纳入62例MBL/未治疗CLL及BTKi治疗CLL患者,接种两剂重组带状疱疹疫苗(RZV),3个月抗体应答率45%显著低于历史对照63%(p=.03),CD4+ T细胞应答率54%显著低于对照96%(p<.001),仅29%达到抗体与细胞联合应答。

要点

  • MBL/未治疗CLL与BTKi治疗CLL患者RZV抗体应答率45%,低于匹配历史对照的63%。
  • CD4+ T细胞应答率54%,显著低于对照96%,BTKi治疗者更低(32% vs 73%)。
  • 仅29%患者同时获得抗体和细胞应答,需改进该人群疫苗策略。

核心结论

  • MBL/CLL患者对RZV的抗体和细胞免疫应答均低于历史对照,尤其BTKi治疗者细胞应答更差,仅29%达到联合应答。

研究设计与样本

  • 前瞻性研究纳入62例MBL/未治疗CLL(37例)及BTKi治疗CLL(25例)患者,接种两剂RZV间隔2个月,中位年龄68岁。
  • 于首剂后3个月和12个月采用抗糖蛋白E ELISA及双色IFN-γ/IL-2 FLUOROSPOT法评估应答,与年龄性别匹配的历史对照比较。

主要发现

  • 3个月抗体应答率45%,显著低于历史对照63%(p=.03)。
  • MBL/未治疗CLL与BTKi治疗CLL抗体应答率分别为51%和36%,差异无统计学意义(p=.23)。
  • CD4+ T细胞应答率54%,显著低于对照96%(p<.001);BTKi治疗者32%低于未治疗者73%(p=.008)。
  • 仅29%参与者达到抗体与细胞联合应答。
  • 12个月评估的47例中24%抗体滴度低于应答阈值;单因素分析显示低丙种球蛋白血症和BTKi治疗与T细胞应答降低相关。

临床怎么用

  • 应认识到MBL/CLL患者接种RZV后免疫应答率偏低,尤其BTKi治疗者细胞免疫应答更差。
  • 对接受BTKi治疗或伴低丙种球蛋白血症的CLL患者,需考虑优化疫苗接种策略。

局限性

  • 采用历史对照而非同期随机对照,可能存在混杂。
  • 12个月应答评估仅47例,样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Monoclonal B-cell lymphocytosis (MBL) and chronic lymphocytic leukemia (CLL) are clonal B-cell disorders associated with an increased risk of infections and impaired vaccination responses. We investigated the immunogenicity of recombinant zoster vaccine (RZV) in these patients. Individuals with MBL/untreated CLL and Bruton tyrosine kinase inhibitor (BTKi)-treated CLL patients were given two doses of RZV separated by 2 months. Responses assessed at 3 and 12 months from the first dose of RZV by an anti-glycoprotein E ELISA antibody assay and by dual-color Interferon-γ and Interleukin-2FLUOROSPOT assays were compared to historic controls matched by age and sex. About 62 patients (37 MBL/untreated CLL and 25 BTKi-treated CLL) were enrolled with a median age of 68 years at vaccination. An antibody response at 3 months was seen in 45% of participants, which was significantly lower compared to historic controls (63%, p = .03). The antibody response did not significantly differ between MBL/untreated CLL and BTKi-treated CLL (51% vs. 36%, respectively, p = .23). The CD4+ T-cell response to vaccination was significantly lower in study participants compared to controls (54% vs. 96%, p < .001), mainly due to lower responses among BTKi-treated patients compared to untreated MBL/CLL (32% vs. 73%, p = .008). Overall, only 29% of participants achieved combined antibody and cellular responses to RZV. Among participants with response assessment at 12 months (n = 47), 24% had antibody titers below the response threshold. Hypogammaglobulinemia and BTKi therapy were associated with reduced T-cell responses in a univariate analysis. Strategies to improve vaccine response to RZV among MBL/CLL patients are needed.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Muchtar E, Koehler AB, Johnson MJ, et al. Humoral and cellular immune responses to recombinant herpes zoster vaccine in patients with chronic lymphocytic leukemia and monoclonal B cell lymphocytosis. Am J Hematol. 2021. PMID: 34699616. doi:10.1002/ajh.26388

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。